A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome
一项针对有肿瘤溶解综合征风险患者的随机试验,比较单剂量拉布立酶与每日五次给药的疗效
期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdr490
Vadhan-Raj, S; Fayad, L E; Fanale, M A; Pro, B; Rodriguez, A; Hagemeister, F B; Bueso-Ramos, C E; Zhou, X; McLaughlin, P W; Fowler, N; Shah, J; Orlowski, R Z; Samaniego, F; Wang, M; Cortes, J E; Younes, A; Kwak, L W; Sarlis, N J; Romaguera, J E